Avecho Biotechnology【AVE】銘柄情報

Avecho Biotechnology Limited (AVE) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.023

( 9.52% )

買値

0.022

売値

0.023

出来高

28,177,155

0.021 日の範囲 0.024

0.0035 52 週間の範囲 0.027

時価総額

84.49M

前日終値

0.021

始値

0.021

時刻

133940

0.023

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

AUD 13,817,588

発行済株式数

3,673,463,679

配当利回り

PER

-17.14

1 株当たり利益 (EPS)

-0

歳入

1.24M

純利益

-4.42M

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. T... Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

avecho.com.au

本社

Clayton, Australia

設立

1992

Avecho Biotechnology Limited is listed in the Healthcare sector of the オーストラリア証券取引所 with ticker AVE. The last closing price for Avecho Biotechnology was AUD0.02. Over the last year, Avecho Biotechnology shares have traded in a share price range of AUD 0.0035 to AUD 0.027.

Avecho Biotechnology currently has 3,673,463,679 shares in issue. The market capitalisation of Avecho Biotechnology is AUD84.49 million. Avecho Biotechnology has a price to earnings ratio (PE ratio) of -17.14.

Aventis Named to List of Top 100 Companies for Working Mothers

Aventis Named to List of Top 100 Companies for Working Mothers Receives Honors Three Years Running BRIDGEWATER, N.J., Sept. 21...

The sanofi-aventis Group Thanks Its Team Members and Shareholders and Launches Its New Visual Identity

The sanofi-aventis Group Thanks Its Team Members and Shareholders and Launches Its New Visual Identity PARIS, Sept. 16 /PRNewswire-FirstCall/...

Aventis to Move Forward With Reissuance Process for Contested Lovenox Patent

Aventis to Move Forward With Reissuance Process for Contested Lovenox Patent BRIDGEWATER, N.J., July 27 /PRNewswire-FirstCall/ -- Aventis...

New Data Confirm Lovenox(R) is an Effective Antithrombotic for Treatment of Acute Coronary Syndromes

New Data Confirm Lovenox(R) is an Effective Antithrombotic for Treatment of Acute Coronary Syndromes SYNERGY, A to Z and a Systematic Overview of...

Sanofi-Synthelabo's Offer for Aventis Expiration Date of Offers

Sanofi-Synthelabo's Offer for Aventis Expiration Date of Offers PARIS, June 23 /PRNewswire-FirstCall/ -- On June 22, 2004, the Autorite...

Sanofi-Synthelabo's Offer for Aventis; Adjustment of Offer Terms on Approval of Aventis Dividend

Sanofi-Synthelabo's Offer for Aventis; Adjustment of Offer Terms on Approval of Aventis Dividend PARIS, June 14 /PRNewswire-FirstCall/...

Sanofi-Synthelabo's Offer for Aventis Expiration Date of Offers

Sanofi-Synthelabo's Offer for Aventis Expiration Date of Offers PARIS, June 1 /PRNewswire-FirstCall/ -- On June 1, 2004, the Autorite des marches...

Aventis and U.S. NIH Enter Into Pandemic Influenza Vaccine Agreement

Aventis and U.S. NIH Enter Into Pandemic Influenza Vaccine Agreement World's Largest Vaccine Developer to Produce Investigational Vaccine...

Sanofi-Synthelabo's Offer for Aventis U.S. Offer Extended to Wednesday, June 30, 2004

Sanofi-Synthelabo's Offer for Aventis U.S. Offer Extended to Wednesday, June 30, 2004 PARIS, May 26 /PRNewswire-FirstCall/ -- Sanofi-Synthelabo...

Data Show Once-Daily Alvesco(R) (ciclesonide) Has No Effect on HPA-Axis Function in Asthma Patients

Data Show Once-Daily Alvesco(R) (ciclesonide) Has No Effect on HPA-Axis Function in Asthma Patients Findings Presented Suggest Minimal Potential...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.002	9.52380952381	0.021	0.025	0.017	31356185	0.02163119	DE
4	0.011	91.6666666667	0.012	0.027	0.0115	27563972	0.01943014	DE
12	0.014	155.555555556	0.009	0.027	0.0085	14826899	0.01618886	DE
26	0.0135	142.105263158	0.0095	0.027	0.008	9859305	0.01415766	DE
52	0.019	475	0.004	0.027	0.0035	7374703	0.01187475	DE
156	0.018	360	0.005	0.027	0.001	5554923	0.00804721	DE
260	0.005	27.7777777778	0.018	0.027	0.001	3844029	0.00853596	DE